Inspire Medical Systems (NYSE:INSP) Rating Increased to Strong-Buy at Zacks Research

Zacks Research upgraded shares of Inspire Medical Systems (NYSE:INSP) from a hold rating to a strong-buy rating in a research note issued to investors on Monday,Zacks.com reports.

A number of other equities research analysts also recently weighed in on the company. Wells Fargo & Company cut their price target on Inspire Medical Systems from $70.00 to $56.00 and set an “equal weight” rating for the company in a research note on Tuesday, May 5th. Freedom Capital raised shares of Inspire Medical Systems to a “strong-buy” rating in a research report on Tuesday, June 30th. Summit Redstone set a $39.00 target price on shares of Inspire Medical Systems in a research report on Friday, May 22nd. Stifel Nicolaus set a $75.00 price target on shares of Inspire Medical Systems in a research note on Tuesday, August 4th. Finally, Royal Bank Of Canada reaffirmed a “sector perform” rating and issued a $60.00 price objective on shares of Inspire Medical Systems in a research note on Tuesday, August 4th. Two investment analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating, eleven have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Inspire Medical Systems presently has a consensus rating of “Hold” and a consensus target price of $66.19.

Inspire Medical Systems Stock Performance

Inspire Medical Systems stock opened at $57.43 on Monday. The firm has a market cap of $1.66 billion, a PE ratio of 12.43, a P/E/G ratio of 4.34 and a beta of 0.70. The firm’s 50 day moving average price is $49.98 and its two-hundred day moving average price is $52.92. Inspire Medical Systems has a twelve month low of $38.91 and a twelve month high of $147.03.

Inspire Medical Systems (NYSE:INSP) last posted its quarterly earnings results on Monday, August 3rd. The company reported $0.14 EPS for the quarter, beating the consensus estimate of ($0.24) by $0.38. Inspire Medical Systems had a net margin of 15.03% and a return on equity of 8.64%. The business had revenue of $200.58 million for the quarter, compared to analysts’ expectations of $194.72 million. During the same period in the previous year, the company posted $0.45 EPS. Inspire Medical Systems’s revenue was down 7.6% on a year-over-year basis. Inspire Medical Systems has set its FY 2026 guidance at 1.050-1.450 EPS. Equities analysts anticipate that Inspire Medical Systems will post 1.24 EPS for the current fiscal year.

Insiders Place Their Bets

In other Inspire Medical Systems news, insider Jason P. Kelly sold 963 shares of the firm’s stock in a transaction on Friday, August 7th. The shares were sold at an average price of $59.55, for a total value of $57,346.65. Following the sale, the insider directly owned 18,985 shares in the company, valued at $1,130,556.75. This trade represents a 4.83% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 2.20% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Inspire Medical Systems

Several hedge funds have recently made changes to their positions in INSP. Palo Alto Investors LP bought a new stake in shares of Inspire Medical Systems in the second quarter valued at about $391,319,000. Empowered Funds LLC bought a new position in Inspire Medical Systems during the second quarter valued at about $2,260,000. Corient Private Wealth LP acquired a new position in Inspire Medical Systems in the 2nd quarter valued at approximately $2,567,000. Bank of America Corp DE acquired a new position in Inspire Medical Systems in the 2nd quarter valued at approximately $11,099,000. Finally, Freestone Grove Partners LP bought a new stake in shares of Inspire Medical Systems in the 2nd quarter worth approximately $348,000. Institutional investors own 94.91% of the company’s stock.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.